GLP-1 drugs may help slow kidney disease in people with these disorders: Study

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists (GLP-1 RAs), originally for type 2 diabetes and obesity, showed promise in slowing kidney disease progression and lowering cardiovascular risks in lupus patients.